[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Definium Therapeutics Inc (DFTX)

Definium Therapeutics Inc (DFTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,440,607
  • Shares Outstanding, K 99,698
  • Annual Sales, $ 0 K
  • Annual Income, $ -183,790 K
  • EBIT $ -193 M
  • EBITDA $ -195 M
  • 60-Month Beta 2.37
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 8.75

Options Overview Details

View History
  • Implied Volatility 91.57% (-45.07%)
  • Historical Volatility 138.57%
  • IV Percentile 69%
  • IV Rank 29.21%
  • IV High 162.76% on 06/03/26
  • IV Low 62.19% on 04/15/26
  • Expected Move (DTE 25) 5.75 (15.56%)
  • Put/Call Vol Ratio 0.11
  • Today's Volume 26,981
  • Volume Avg (30-Day) 3,935
  • Put/Call OI Ratio 0.22
  • Today's Open Interest 55,798
  • Open Int (30-Day) 64,078
  • Expected Range 31.24 to 42.74

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.55
  • Number of Estimates 5
  • High Estimate $-0.51
  • Low Estimate $-0.58
  • Prior Year $-0.50
  • Growth Rate Est. (year over year) -10.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
21.69 +78.08%
on 06/09/26
39.16 -1.37%
on 06/22/26
+16.13 (+71.67%)
since 05/22/26
3-Month
17.13 +125.48%
on 03/30/26
39.16 -1.37%
on 06/22/26
+20.23 (+109.92%)
since 03/20/26
52-Week
6.34 +509.23%
on 06/23/25
39.16 -1.37%
on 06/22/26
+31.58 (+447.87%)
since 06/20/25

Most Recent Stories

More News
Stocks Erase Early Gains as Alphabet and Software Companies Fall

The S&P 500 Index ($SPX ) (SPY ) today is down -0.40%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.27%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.30%. September E-mini S&P futures...

MSTR : 109.62 (-2.59%)
GOOGL : 347.16 (-5.67%)
SNDK : 2,322.89 (+6.32%)
COIN : 164.96 (+1.04%)
STX : 1,093.63 (+2.19%)
AMD : 544.50 (+1.33%)
DFTX : 37.56 (+53.43%)
^BTCUSD : 64,448.05 (+2.02%)
SPY : 744.76 (-0.27%)
NOC : 507.74 (-2.64%)
FRVO : 36.35 (+3.59%)
ADSK : 186.41 (-3.82%)
Stocks Supported by Strength in Chipmakers and AI-Infrastructure Stocks

The S&P 500 Index ($SPX ) (SPY ) today is up +0.21%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.54%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.50%. September E-mini S&P futures...

MSTR : 109.62 (-2.59%)
AMAT : 624.94 (+1.27%)
GOOGL : 347.16 (-5.67%)
SNDK : 2,322.89 (+6.32%)
GLXY : 33.82 (-1.11%)
$IUXX : 30,261.78 (-0.47%)
COIN : 164.96 (+1.04%)
ZNU26 : 109-065 (-0.11%)
LGND : 261.02 (-5.04%)
APGE : 132.61 (+46.72%)
ESU26 : 7,540.00 (-0.04%)
STX : 1,093.63 (+2.19%)
Definium Therapeutics Announces Positive Topline Results from Phase 3 Emerge Study of DT120 Orally Disintegrating Tablet (ODT) in Major Depressive Disorder

Study met primary and all key secondary efficacy endpoints 8.1 point Montgomery-Åsberg Depression Rating Scale (MADRS) placebo-adjusted change from baseline at Week 6...

DFTX : 37.56 (+53.43%)
Definium Therapeutics to Discuss Topline Results from Phase 3 Emerge Study in Major Depressive Disorder on June 22, 2026

Company to host webcast tomorrow at 8:00 a.m. EDT

DFTX : 37.56 (+53.43%)
Definium Therapeutics Announces New Employee Inducement Grants

Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes...

DFTX : 37.56 (+53.43%)
Definium Therapeutics Announces New Employee Inducement Grants

Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes...

DFTX : 37.56 (+53.43%)
Definium Therapeutics Eyes Key DT-120 Depression Data, Advances Anxiety Program

Definium Therapeutics (NASDAQ:DFTX) Chief Financial Officer Brandi Roberts said the company is preparing for several key clinical and regulatory milestones for DT-120, including anticipated Phase III data...

DFTX : 37.56 (+53.43%)
Definium Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference

Definium Therapeutics, Inc. (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological...

DFTX : 37.56 (+53.43%)
Definium Therapeutics Announces First Patient Dosed in Ascend, the Second Phase 3 Pivotal Study of DT120 ODT in Major Depressive Disorder

The primary endpoint will measure the change from baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) score at Week 6 between DT120 Orally Disintegrating Tablet (ODT) 100 µg and placebo...

DFTX : 37.56 (+53.43%)
Definium Therapeutics Announces New Employee Inducement Grants

Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes...

DFTX : 37.56 (+53.43%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed above 80%. The market has entered extreme overbought territory.

See More Share

Business Summary

Definium Therapeutics, Inc. is developing therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Definium Therapeutics Inc., formerly known as Mind Medicine Inc., is based in NEW YORK....

See More

Key Turning Points

3rd Resistance Point 26.67
2nd Resistance Point 25.96
1st Resistance Point 25.22
Last Price 37.56
1st Support Level 23.77
2nd Support Level 23.06
3rd Support Level 22.32

See More

52-Week High 39.16
Last Price 37.56
Fibonacci 61.8% 26.62
Fibonacci 50% 22.75
Fibonacci 38.2% 18.88
52-Week Low 6.34

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.